Path to drugging functional clones of luminal breast cancers using in-depth proteomics with spatially resolved mass spectrometry guided by MALDI imaging
View ORCID ProfileN. Hajjaji, View ORCID ProfileS. Aboulouard, View ORCID ProfileT. Cardon, D. Bertin, View ORCID ProfileYM. Robin, View ORCID ProfileI. Fournier, View ORCID ProfileM. Salzet
doi: https://doi.org/10.1101/2021.02.16.21251694
N. Hajjaji
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
2Breast Cancer Unit, Oscar Lambret Center, F-59000 Lille, France
S. Aboulouard
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
T. Cardon
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
D. Bertin
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
2Breast Cancer Unit, Oscar Lambret Center, F-59000 Lille, France
YM. Robin
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
2Breast Cancer Unit, Oscar Lambret Center, F-59000 Lille, France
I. Fournier
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
3Institut universitaire de France, 75000 Paris
M. Salzet
1Univ. Lille, Inserm, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), F-59000 Lille, France
3Institut universitaire de France, 75000 Paris
Data Availability
All raw data are available as supplementary material files and on ProteomeXchange with identifier PXD024134.
Posted February 19, 2021.
Path to drugging functional clones of luminal breast cancers using in-depth proteomics with spatially resolved mass spectrometry guided by MALDI imaging
N. Hajjaji, S. Aboulouard, T. Cardon, D. Bertin, YM. Robin, I. Fournier, M. Salzet
medRxiv 2021.02.16.21251694; doi: https://doi.org/10.1101/2021.02.16.21251694
Path to drugging functional clones of luminal breast cancers using in-depth proteomics with spatially resolved mass spectrometry guided by MALDI imaging
N. Hajjaji, S. Aboulouard, T. Cardon, D. Bertin, YM. Robin, I. Fournier, M. Salzet
medRxiv 2021.02.16.21251694; doi: https://doi.org/10.1101/2021.02.16.21251694
Subject Area
Subject Areas
- Addiction Medicine (325)
- Allergy and Immunology (633)
- Anesthesia (168)
- Cardiovascular Medicine (2408)
- Dermatology (208)
- Emergency Medicine (382)
- Epidemiology (11811)
- Forensic Medicine (10)
- Gastroenterology (705)
- Genetic and Genomic Medicine (3778)
- Geriatric Medicine (350)
- Health Economics (637)
- Health Informatics (2413)
- Health Policy (941)
- Hematology (343)
- HIV/AIDS (789)
- Medical Education (370)
- Medical Ethics (105)
- Nephrology (402)
- Neurology (3533)
- Nursing (199)
- Nutrition (530)
- Oncology (1836)
- Ophthalmology (541)
- Orthopedics (222)
- Otolaryngology (287)
- Pain Medicine (234)
- Palliative Medicine (67)
- Pathology (448)
- Pediatrics (1040)
- Primary Care Research (424)
- Public and Global Health (6192)
- Radiology and Imaging (1295)
- Respiratory Medicine (833)
- Rheumatology (380)
- Sports Medicine (324)
- Surgery (407)
- Toxicology (51)
- Transplantation (173)
- Urology (148)